CN Patent

CN105873591A — 用于治疗肾细胞癌（rcc）的6-氧代-1,6-二氢-哒嗪衍生物

Assigned to Merck Patent GmbH · Expires 2016-08-17 · 10y expired

What this patent protects

用于治疗肾细胞癌（RCC）的3‑(1‑{3‑[5‑(1‑甲基‑哌啶‑4‑基甲氧基)‑嘧啶‑2‑基]‑苄基}‑6‑氧代‑1,6‑二氢‑哒嗪‑3‑基)‑苄腈或其可药用盐和/或溶剂化物。

USPTO Abstract

用于治疗肾细胞癌（RCC）的3‑(1‑{3‑[5‑(1‑甲基‑哌啶‑4‑基甲氧基)‑嘧啶‑2‑基]‑苄基}‑6‑氧代‑1,6‑二氢‑哒嗪‑3‑基)‑苄腈或其可药用盐和/或溶剂化物。

Drugs covered by this patent

Patent Metadata

Patent number
CN105873591A
Jurisdiction
CN
Classification
—
Expires
2016-08-17
Drug substance claim
No
Drug product claim
No
Assignee
Merck Patent GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.